Researcher Profiles

Return to member profile

Joseph R. Bertino, MD

Publications since 2011

Tedeschi, P. M. Lin, H. Gounder, M. Kerrigan, J. E. Abali, E. E. Scotto, K. Bertino, J. Suppression of Cytosolic NADPH Pool by Thionicotinamide Increases Oxidative Stress and Synergizes with Chemotherapy. Mol Pharmacol, In process, . (PMID: 26219913)

Tedeschi, P. M. Vazquez, A. Kerrigan, J. E. Bertino, J. R. Mitochondrial Methylene Tetrahydrofolate Dehydrogenase (MTHFD2) Overexpression is Associated with Tumor Cell Proliferation and is a Novel Target for Drug Development. Mol Cancer Res, In process, . (PMID: 26101208)

Bansal, N. Mishra, P. J. Stein, M. DiPaola, R. S. Bertino, J. R. Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells. Oncotarget, In process, . (PMID: 26036314)

Lin, H. Yu, X. Eng, O. S. Buckley, B. Kong, A. N. Bertino, J. R. Carpizo, D. R. Gounder, M. K. A sensitive liquid chromatography-mass spectrometry bioanalytical assay for a novel anticancer candidate - ZMC1. Biomed Chromatogr, In process, . (PMID: 25944179)

Tedeschi, P. M. Kathari, Y. K. Johnson-Farley, N. Bertino, J. R. Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination. Cancer Chemother Pharmacol, In process, . (PMID: 25917288)

DiFranco, K. M. Johnson-Farley, N. Bertino, J. R. Elson, D. Vega, B. A. Belinka, B. A. Jr Kachlany, S. C. LFA-1-targeting Leukotoxin (LtxA; Leukothera) causes lymphoma tumor regression in a humanized mouse model and requires caspase-8 and Fas to kill malignant lymphocytes. Leuk Res, In process, . (PMID: 25850729)

Tedeschi, P. M. Johnson-Farley, N. Lin, H. Shelton, L. M. Ooga, T. Mackay, G. Van Den Broek, N. Bertino, J. R. Vazquez, A. Quantification of folate metabolism using transient metabolic flux analysis. Cancer Metab, 3:6, . (PMID: 26023330, PMCID: PMC4446824)

Bansal, N. Johnson Farley, N. Wu, L. Lewis, J. Youssoufian, H. Bertino, J. R. Darinaparsin inhibits prostate tumor initiating cells and Du 145 xenografts and is an inhibitor of hedgehog signaling. Mol Cancer Ther, In process, . (PMID: 25381261)

Johnson-Farley, N. Veliz, J. Bhagavathi, S. Bertino, J. R. ABT-199, a BH3 Mimetic That Specifically Targets Bcl-2, Enhances the Antitumor Activity of Chemotherapy, Bortezomib, and JQ1 in "Double Hit " Lymphoma cells. Leuk Lymphoma, In process, . (PMID: 25373508)

Tedeschi, P. M. Kathari, Y. K. Farooqi, I. N. Bertino, J. R. Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts. Cancer Chemother Pharmacol, 74:1029-1032, . (PMID: 25205429, PMCID: PMC4209237)

Munshi, P. N. Lubin, M. Bertino, J. R. 6-Thioguanine: A Drug With Unrealized Potential for Cancer Therapy. Oncologist, 19:760-765, . (PMID: 24928612, PMCID: PMC4077447)

Capaccione, K. M. Hong, X. Morgan, K. M. Liu, W. Bishop, J. M. Liu, L. Markert, E. Deen, M. Minerowicz, C. Bertino, J. R. Allen, T. Pine, S. R. Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma. Oncotarget, 5:3636-3650, . (PMID: 25004243, PMCID: PMC4116509)

Xie, X. Bansal, N. Shaik, T. Kerrigan, J. E. Minko, T. Garbuzenko, O. Abali, E. E. Johnson-Farley, N. Banerjee, D. Scotto, K. W. Bertino, J. R. A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts. Oncotarget, 5:901-907, . (PMID: 24658650, PMCID: PMC4011592)

Bansal, N. Davis, S. Tereshchenko, I. Budak-Alpdogan, T. Zhong, H. Stein, M. N. Kim, I. Y. Dipaola, R. S. Bertino, J. R. Sabaawy, H. E. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate, 74:187-200, . (PMID: 24154958, PMCID: PMC3939797)

Xie, X. Kerrigan, J. E. Minko, T. Garbuzenko, O. Lee, K. C. Scarborough, A. Abali, E. E. Budak-Alpdogan, T. Johnson-Farley, N. Banerjee, D. Scotto, K. W. Bertino, J. R. Antitumor and modeling studies of a penetratin-peptide that targets E2F-1 in small cell lung cancer. Cancer Biol Ther, 14:742-751, . (PMID: 23792570)

Hsieh, Y. C. Tedeschi, P. Adebisi Lawal, R. Banerjee, D. Scotto, K. Kerrigan, J. E. Lee, K. C. Johnson-Farley, N. Bertino, J. R. Abali, E. E. Enhanced Degradation of Dihydrofolate Reductase through Inhibition of NAD Kinase by Nicotinamide Analogs. Mol Pharmacol, 83:339-353, . (PMID: 23197646, PMCID: PMC3558814)

Bertino, J. R. Vazquez, A. Tedeschi, P. M. Over expression of the mitochondrial folate and glycine-serine pathway: a new determinant of methotrexate selectivity in tumors. Cancer Res, 73:478-482, . (PMID: 23135910)

Tedeschi, P. M. Markert, E. K. Gounder, M. Lin, H. Dvorzhinski, D. Dolfi, S. C. Chan, L. L. Qiu, J. Dipaola, R. S. Hirshfield, K. M. Boros, L. G. Bertino, J. R. Oltvai, Z. N. Vazquez, A. Contribution of serine, folate and glycine metabolism to the ATP, NADPH and purine requirements of cancer cells. Cell Death Dis, 4:e877, . (PMID: 24157871, PMCID: PMC3920946)

Dolfi, S. C. Chan, L. L. Qiu, J. Tedeschi, P. M. Bertino, J. R. Hirshfield, K. M. Oltvai, Z. N. Vazquez, A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab, 1:20, . (PMID: 24279929)

Budak-Alpdogan, T. Jeganathan, G. Lee, K. C. Mrowiec, Z. R. Medina, D. J. Todd, D. Moore, D. Bertino, J. R. Strair, R. Irradiated allogeneic cells enhance umbilical cord blood stem cell engraftment in immunodeficient mice. Bone Marrow Transplant, 47:1569-1576, . (PMID: 22609880)

Roussel, B. Johnson-Farley, N. Kerrigan, J. E. Scotto, K. W. Banerjee, D. Felczak, K. Pankiewicz, K. W. Gounder, M. Lin, H. Abali, E. E. Bertino, J. R. A second target of benzamide riboside: Dihydrofolate reductase. Cancer Biol Ther, 13:1290-1298, . (PMID: 22954684, PMCID: PMC3493437)

Bertino, J. R. Lubin, M. Johnson-Farley, N. Chan, W. C. Goodell, L. Bhagavathi, S. Lack of Expression of MTAP in Uncommon T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk, 12:306-309, . (PMID: 23040436)

Lin, H. Gounder, M. K. Bertino, J. R. Kong, A. N. DiPaola, R. S. Stein, M. N. A validated HPLC assay for the determination of R-(-)-gossypol in human plasma and its application in clinical pharmacokinetic studies. J Pharm Biomed Anal, 66:371-375, . (PMID: 22483642, PMCID: PMC3358459)

Gounder, M. K. Lin, H. Stein, M. Goodin, S. Bertino, J. R. Kong, A. N. DiPaola, R. S. A validated bioanalytical HPLC method for pharmacokinetic evaluation of 2-deoxyglucose in human plasma. Biomed Chromatogr, 26:650-654, . (PMID: 21932382)

Collins, C. C. Volik, S. V. Lapuk, A. V. Wang, Y. Gout, P. W. Wu, C. Xue, H. Cheng, H. Haegert, A. Bell, R. H. Brahmbhatt, S. Anderson, S. Fazli, L. Hurtado-Coll, A. Rubin, M. A. Demichelis, F. Beltran, H. Hirst, M. Marra, M. Maher, C. A. Chinnaiyan, A. M. Gleave, M. Bertino, J. R. Lubin, M. Wang, Y. Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target. Mol Cancer Ther, 11:775-783, . (PMID: 22252602)

Barboza, N. M. Medina, D. J. Budak-Alpdogan, T. Aracil, M. Jimeno, J. M. Bertino, J. R. Banerjee, D. Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab. Cancer Biol Ther, 13:114-122, . (PMID: 22336911, PMCID: PMC3336068)

Kamen, B. A. Bertino, J. R. Holcenberg, J. S. Bleyer, W. A. Are we getting closer to using methotrexate in an optimal manner? J Clin Oncol, 29:3493-4; author reply 3494, . (PMID: 21810689)

Bertino, J. R. Waud, W. R. Parker, W. B. Lubin, M. Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies. Cancer Biol Ther, 11:627-632, . (PMID: 21301207, PMCID: PMC3084968)

Moroz, M. A. Kochetkov, T. Cai, S. Wu, J. Shamis, M. Nair, J. de Stanchina, E. Serganova, I. Schwartz, G. K. Banerjee, D. Bertino, J. R. Blasberg, R. G. Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging. Clin Cancer Res, 17:1099-1110, . (PMID: 21245090, PMCID: PMC3079195)